ArticleFrontiers in genetics2025
Identification and validation of calcium signaling pathway-related biomarkers in T1 and T2 lymph node metastatic gastric cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CSN3 promotes gastric cancer progression and is associated with immune infiltration and inflammatory signaling.Translational cancer research · 2026Article
- Identification the Tumor Mechanics-Related Biomarkers in Gastric Cancer Patients Based on Bioinformatics and Machine Learning.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node (LN) status is crucial for assessing the treatment effectiveness and potential for cure in early gastric cancer (GC; T1-T2), whether treated through endoscopy or surgery. The purpose of this study was to identify biomarkers related to calcium signaling pathway in T1 and T2 lymph node metastatic gastric cancer and explore potential regulatory mechanisms. Methods: All data applied in this study were obtained from public databases. Biomarkers were identified through univariate Cox regression analysis and survival analysis. Subsequently, enrichment analysis, somatic mutation analysis, immune microenvironment analysis, drug sensitivity analysis, and single cell analysis were used to investigate the functional mechanisms. Finally, clinical sample validation was performed. Results: RET was identified as a biomarker through selection. Enrichment analysis indicated that 36 significantly different pathways between the NP (LN-positive samples (N1, N2, N3)) and NO (LN-negative samples (N0)) groups. A total of 2 oncogenic pathways showed significant differences between the NP and NO groups. The scores of 14 immune cell types showed significant differences, including mast cells. RET exhibited the strongest correlation with mast cells. The ESTIMATE score, stromal score, and immune score were significantly elevated in the NP group. Additionally, the NP group showed significantly higher expression of 13 immune checkpoint genes. TP53 had the highest mutation rate in both the NP and NO groups. There was a significant difference in the sensitivity to 15 chemotherapy drugs between the NP and NO groups. Additionally, RET was expressed in multiple cell types, including fibroblasts and mast cells. In both the TCGA-GC-LN and GSE84433 datasets, RET was significantly upregulated in the NP group. The RT-qPCR results of clinical samples also indicated a significant upregulation of RET in the NP group. Conclusion: RET laid the foundation for targeted therapy in the treatment of T1 and T2 lymph node metastatic gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.